Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06690970 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 2 to 3
    • Study description expanded, about 5 words
    v5
  2. Study sites: 1 to 2v4
  3. Interventions: 68Ga/18F-PSMA (Diagnostic Test) to 68Ga/18F-PSMA/PSFA (Diagnostic Test)
    • Study description revised
    v3
  4. Start date: Sep 1, 2024 to Sep 1, 2020v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer, hepatic cancer, etc.).
Trial Details
NCT Number NCT06690970
Lead Sponsor Tianjin Medical University
Collaborators: Tianjin Medical University General Hospital
Conditions
(from sponsor)		 PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis, FAP, Hepatic Cancer
Related terms Liver Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov